| Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19 C Cervia, J Nilsson, Y Zurbuchen, A Valaperti, J Schreiner, ... Journal of Allergy and Clinical Immunology 147 (2), 545-557. e9, 2021 | 414 | 2021 |
| Immunoglobulin signature predicts risk of post-acute COVID-19 syndrome C Cervia, Y Zurbuchen, P Taeschler, T Ballouz, D Menges, S Hasler, ... Nature Communications 13 (1), 1-12, 2022 | 174 | 2022 |
| A distinct innate immune signature marks progression from mild to severe COVID-19 S Chevrier, Y Zurbuchen, C Cervia, S Adamo, ME Raeber, N de Souza, ... Cell Reports Medicine 2 (1), 2021 | 134 | 2021 |
| Signature of long-lived memory CD8+ T cells in acute SARS-CoV-2 infection S Adamo, J Michler, Y Zurbuchen, C Cervia, P Taeschler, ME Raeber, ... Nature 602 (7895), 148-155, 2022 | 105 | 2022 |
| Profound dysregulation of T cell homeostasis and function in patients with severe COVID‐19 S Adamo, S Chevrier, C Cervia, Y Zurbuchen, ME Raeber, L Yang, ... Allergy 76 (9), 2866-2881, 2021 | 69 | 2021 |
| Autoantibodies against chemokines post-SARS-CoV-2 infection correlate with disease course J Muri, V Cecchinato, A Cavalli, AA Shanbhag, M Matkovic, M Biggiogero, ... Nature immunology 24 (4), 604-611, 2023 | 45 | 2023 |
| Molecular states during acute COVID-19 reveal distinct etiologies of long-term sequelae RC Thompson, NW Simons, L Wilkins, E Cheng, DM Del Valle, ... Nature Medicine 29 (1), 236-246, 2023 | 35 | 2023 |
| Autoantibodies in COVID‐19 correlate with antiviral humoral responses and distinct immune signatures P Taeschler, C Cervia, Y Zurbuchen, S Hasler, C Pou, Z Tan, S Adamo, ... Allergy 77 (8), 2415-2430, 2022 | 34 | 2022 |
| Persistent complement dysregulation with signs of thromboinflammation in active Long Covid C Cervia-Hasler, SC Brüningk, T Hoch, B Fan, G Muzio, RC Thompson, ... Science 383 (6680), eadg7942, 2024 | 27 | 2024 |
| Early peak and rapid decline of SARS-CoV-2 seroprevalence in a Swiss metropolitan region M Emmenegger, E De Cecco, D Lamparter, RPB Jacquat, D Ebner, ... MedRxiv 531, 20118554, 2020 | 24 | 2020 |
| T‐cell recovery and evidence of persistent immune activation 12 months after severe COVID‐19 P Taeschler, S Adamo, Y Deng, C Cervia, Y Zurbuchen, S Chevrier, ... Allergy 77 (8), 2468-2481, 2022 | 22 | 2022 |
| Lymphopenia-induced T cell proliferation is a hallmark of severe COVID-19 S Adamo, S Chevrier, C Cervia, Y Zurbuchen, ME Raeber, L Yang, ... BioRxiv, 2020.08. 04.236521, 2020 | 18 | 2020 |
| Human memory B cells show plasticity and adopt multiple fates upon recall response to SARS-CoV-2 Y Zurbuchen, J Michler, P Taeschler, S Adamo, C Cervia, ME Raeber, ... Nature Immunology 24 (6), 955-965, 2023 | 13 | 2023 |
| Early plateau of SARS-CoV-2 seroprevalence identified by tripartite immunoassay in a large population M Emmenegger, E De Cecco, D Lamparter, RPB Jacquat, D Ebner, ... Medrxiv, 2020, 2020 | 13 | 2020 |
| Population-wide evolution of SARS-CoV-2 immunity tracked by a ternary immunoassay M Emmenegger, E De Cecco, D Lamparter, RPB Jacquat, J Riou, ... | 9 | 2020 |
| Continuous population-level monitoring of SARS-CoV-2 seroprevalence in a large European metropolitan region M Emmenegger, E De Cecco, D Lamparter, RPB Jacquat, J Riou, ... Iscience 26 (2), 2023 | 6 | 2023 |
| Exposure to avian coronavirus vaccines is associated with increased levels of SARS‐CoV‐2‐cross‐reactive antibodies O Ardicli, KT Carli, P Satitsuksanoa, A Dreher, A Cusini, S Hutter, D Mirer, ... Allergy 77 (12), 3648-3662, 2022 | 3 | 2022 |
| Anti-chemokine antibodies after SARS-CoV-2 infection correlate with favorable disease course J Muri, V Cecchinato, A Cavalli, AA Shanbhag, M Matkovic, M Biggiogero, ... bioRxiv, 2022 | 2 | 2022 |
| Corrections & amendments Y Zurbuchen, J Michler, P Taeschler, S Adamo, C Cervia, ME Raeber, ... | | 2023 |
| Publisher Correction: Human memory B cells show plasticity and adopt multiple fates upon recall response to SARS-CoV-2 Y Zurbuchen, J Michler, P Taeschler, S Adamo, C Cervia, ME Raeber, ... Nature Immunology 24 (11), 1961, 2023 | | 2023 |
